2019 MOTIVATE Course 4: Behavioural Aspects of MOH

2019 MOTIVATE Course 4: Behavioural Aspects of MOH

Current Status
Not Enrolled
Get Started

1 Category 2 points with the RACGP

1 Core PDP point

All participants will be awarded a certificate of completion for self-reporting to other colleges

Duration: 30 minutes

MOH is said to be a biobehavioural disorder, wherein patients believe that they need their headache medication to function. Comorbid psychiatric disorders are also common among these patients. Learn about strategies for patient education and individualising management.

Learning objectives:
Upon completing this course, participants will be able to:

  • State why MOH can be considered a biobehavioural disorder
  • List basic psychological issues that contribute to MOH
  • Put in place a system for screening patients with MOH for possible psychological comorbidities such as depression and anxiety disorder.
  • Associate Professor Richard Stark, Alfred Hospital, Melbourne, Victoria
  • Professor Mieke Van Driel, School of Medicine, University of Queensland, Herston, Queensland
  • Associate Professor Treasure McGuire, School of Pharmacy, University of Queensland, Queensland; Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland
  • Dr Brett McFarlane, The Australian College of Pharmacy, Canberra, Australian Capital Territory
  • Professor Deborah Turnbull, School of Psychology, University of Adelaide, South Australia

  • Royal Australian College of General Practitioners:
    • 1 Category Two QI&CPD points
    • Activity no. 110005
  • Australian College of Rural and Remote Medicine:
    • 1 Core PDP point
    • Activity no. 10381
  • Pharmacists and nurses are invited to access this continuing professional development activity. At the end, a certificate may be downloaded as proof of completion.

Dr Lara Mihaljevic
General Practitioner
Drummoyne Medical Centre, Victoria Road, Drummoyne, NSW

  • Faculty
    • Associate Professor Richard Stark: Co-authored a clinical paper sponsored by Pfizer on the safety of eletriptan. Between 2012 and 2014 received consulting and lecture fees from Allergan and lecture fees from MSD on chronic migraine
    • Professor Mieke Van Driel: No conflict of interest
    • Associate Professor Treasure McGuire: No conflict of interest
    • Dr Brett McFarlane: No conflict of interest
    • Professor Deborah Turnbull: Received research grants and co-authored papers on hypertension sponsored by pharmaceutical companies, including Pfizer Pty. Ltd., between 1999 and 2006
  • GP reviewer
    • Dr Lara Mihaljevic: No conflict of interest
  • Non-faculty: employees of In Vivo Academy involved in producing the content of this course, Yulyana, Tina Garcia, Monica Kurniawan and Lisa Sullivan, declare no conflict of interest.